Ai-powered Drug Discovery
BullFrog AI delivers defensible intelligence for pharmaceutical R&D — biology-aware data harmonization, Causal AI analytics, and structured decision support, built to produce answers you can defend to a scientific review board, a regulatory agency, or a board of directors.
The Core Challenge
Drug development fails more often than it succeeds — and much of that failure is analytical, not scientific.
As organizations scale AI across R&D workflows, many are discovering that volume AI — systems built to generate outputs quickly — produces results that are difficult to reproduce and harder to defend. The question governing every AI investment in drug development is no longer how many analyses were completed. It is how much defensible, actionable intelligence each analytical dollar delivered.
BullFrog AI was built to answer that question.
Technology Architecture
Biology-aware data harmonization — preparing messy bioclinical data for AI consumption, with every cross-dataset combination decision logged and auditable.
Causal AI analytics — identifying patient subgroups and biological drivers of disease across complex, heterogeneous datasets. Developed in partnership with Johns Hopkins University Applied Physics Laboratory.
Structured, auditable decision support — defining what matters through ordered criteria, not numerical weights, and producing defensible recommendations at every decision gate.
Our Delivery Matrix
BullFrog AI turns multi-omic and clinical data into patient subgroups, translational signals, and rankings your committee can review.
Harmonizes multi-omic, clinical, and real-world data across sources and study designs.
Surfaces patient subgroups and translational signals hidden in complex data sets.
Ranks candidates head-to-head against your criteria, with written justification for every call.
Research Partners
bfLEAP® was developed in partnership with JHU APL — one of the U.S. government’s most trusted research institutions — purpose-built for high-stakes, high-dimensional analytical environments where standard statistical approaches fail.
BullFrog’s neuroscience data infrastructure is built in collaboration with the Lieber Institute for Brain Development, providing access to one of the world’s leading repositories of postmortem brain transcriptomics data across multiple brain regions and collection phases.
Every engagement begins with a feasibility study — a defined question, a defined deliverable, a defined timeline — so you can see what your own data yields before committing to a multi-year subscription.
